CRO服务

Tumor vaccine development platform

Basic Information

　　The tumor genome is rich in a large number of gene mutations, and the higher the malignancy, the more mutations there are. A large number of gene mutations inevitably lead to the appearance of mutated proteins on the surface of tumor cells. For the immune system, these proteins are considered as foreign antigens. When the expression of these abnormal proteins is insufficient, an effective immune response may not be triggered.The rational approach is to identify these abnormal proteins and amplify them (antigens) in vitro, that is creating therapeutic tumor vaccines, which can be used to stimulate the immune system. During the immune response, MHC (Major Histocompatibility Complex) participates in the recognition and presentation of antigens. If an antigen bound to MHC proteins can be recognized by T cells, the T cells will attack any cell containing this antigen, thereby achieving the therapeutic goal.These peptides bind to MHC proteins are usually short (10-20 amino acids) in length. Determining the peptide(s) that bind to MHC proteins or combinations of peptides that bind to MHC proteins and can elicit an effective immune response is a key focus in vaccine development process. We can utilize bioinformatics analysis techniques to analyze and predict which peptides may bind to MHC proteins based on the target information provided by client. And drug screening experiments can be conducted using animal models to identify effective peptides or   peptides combinations.

Services We Provide

　　We can utilize bio-informatics analysis techniques to analyze and predict which peptides may bind to MHC proteins based on the target information provided by the client. And drug screening experiments can be conducted using animal models to identify effective peptides (mRNA) or peptides combinations.

Procedure of Services

　　Based on the target information provided by the client (such as aberrant proteins like WT1), we can utilize bio-informatics analysis techniques to analyze and predict which peptides may bind to MHC proteins. Alternatively, if the client has already identified specific peptides for investigation, we can proceed with the analysis accordingly.

　　1.Preparation of vaccine in vitro (mRNA or peptides)

　　2.Construction of stable transfectants of murine cancer cells overexpressing human aberrant protein genes: Murine cancer cells (such as 4T1, CT26, and MFC) are selected based on the disease studied. And then lentiviral vectors carrying human aberrant protein genes with puromycin resistance are packaged. The target murine cancer cells are infected with the lentivirus, followed by puromycin drug screening to obtain stable transfectants.

　　3.Drug screening mouse models for tumor vaccine
　　3.1Prophylactic
　　1）Based on the source of mouse cancer cells, the corresponding mouse strain is selected. The prepared vaccine is injected into mice 3-4 weeks before cell injection (once or twice a week). One week after the final injection, a suitable amount of cells is injected subcutaneously into the mice.
　　2）Observe tumor formation and tumor growth. Once the tumor reaches a certain size, euthanize the mice for further analysis.
　　3）Other immune assays

　　3.2Therapeutic
　　1）Choose the appropriate mouse strain based on the source of mouse cancer cells and inject a suitable amount of cells subcutaneously into the mice.
　　2）When the tumor forms and grows to a certain size,　injecting the prepared vaccine into the mice (once or twice a week) for a total of 3-5 injections.
　　3）Observe the growth of the tumor. Once the tumor reaches a certain size, euthanize the mice for further analysis.
　　4）Other immune assays

Features

　　1.Our bio-informatics analysis platform can provide professional target and vaccine analysis servic.
　　2.Our cell bank offers a variety of mouse cancer cell lines, which allows multiple choices of cell lines to investigate the role of targets in different cancer types.
　　3.Our animal facility can accommodate 1000-2000 mouse cages simultaneously, which helps us to ensure the project punctuality.

Representative Case

Our Laboratory